It may not be an individual decision at all
Similarly, the FDA has approved a number of injectable GLP-1s for type 2 diabetes, such as Ozempic (semaglutide), Mounjaro (tirzepatide), and (semaglutide), an oral GLP-1 medication for blood sugar control in people with type 2 diabetes
This is important because when we're talking about peptide therapeutics
You should consult your GP or a registered dietitian if: You have a BMI below 18.5 kg/m (underweight) or 35 kg/m or above (severe obesity) noting that lower thresholds apply for some ethnic groups (e.g., 27.5 kg/m for some Asian groups) You have a pre-existing medical condition such as type 1 or type 2 diabetes, kidney disease, cardiovascular disease, or a history of an eating disorder You are pregnant, breastfeeding, or planning a pregnancy You are taking prescription medications that may interact with dietary changes You experience unintentional weight loss particularly more than 5% of your body weight over 6 to 12 months, or weight loss accompanied by other concerning symptoms such as persistent gastrointestinal symptoms, difficulty swallowing, rectal bleeding, a new lump, or persistent cough which should be assessed promptly by a GP You feel persistently fatigued, dizzy, or unwell when following a reduced-calorie diet It is also important to recognise signs that a calorie deficit may be too aggressive
Debe estar afiliado en la Parte D para participar
